Argitalpenak (42) NURIA GARCÍA MARCHENA argitalpenak

2023

  1. Antidepressant Medication Does Not Contribute to the Elevated Circulating Concentrations of Acylethanolamides Found in Substance Use Disorder Patients

    International Journal of Molecular Sciences, Vol. 24, Núm. 19

  2. Antipsychotic Medication Influences the Discriminative Value of Acylethanolamides as Biomarkers of Substance Use Disorder

    International journal of molecular sciences, Vol. 24, Núm. 11

  3. Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder

    Drug and Alcohol Dependence, Vol. 245

  4. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  5. Plasma Lysophosphatidic Acid Concentrations in Sex Differences and Psychiatric Comorbidity in Patients with Cocaine Use Disorder

    International Journal of Molecular Sciences, Vol. 24, Núm. 21

  6. Plasma concentrations of lysophosphatidic acid and the expression of its receptors in peripheral blood mononuclear cells are altered in patients with cocaine use disorders

    Translational Psychiatry, Vol. 13, Núm. 1

  7. Sex differences in the comorbidity of patients seeking a first treatment for Alcohol Use Disorder

    International Journal of Mental Health and Addiction

2022

  1. Niveles plasmáticos de midkina en pacientes con trastorno por uso de cocaína en abstinencia

    Adicciones: Revista de socidrogalcohol, Vol. 34, Núm. 4, pp. 273-277

  2. Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex

    Biomedicines, Vol. 10, Núm. 5

  3. Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders

    Brain Sciences, Vol. 12, Núm. 5

  4. Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

    Biomedicines, Vol. 10, Núm. 5

2021

  1. Evaluation of functional status among patients undergoing maintenance treatments for opioid use disorders

    Harm Reduction Journal, Vol. 18, Núm. 1

  2. Evaluation of neurotrophic factors and education level as predictors of cognitive decline in alcohol use disorder

    Scientific Reports, Vol. 11, Núm. 1

  3. Inflammatory factors and depression in substance use disorder

    The Neuroscience of Depression: Genetics, Cell Biology, Neurology, Behavior, and Diet (Elsevier), pp. 149-160

  4. Inflammatory factors and depression in substance use disorder

    The Neuroscience of Depression, 1st Edition: Volume 1-2 (Elsevier), pp. V2-149-V2-160

  5. Influence of gender and education on cocaine users in an outpatient cohort in Spain

    Scientific Reports, Vol. 11, Núm. 1

  6. Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

    Scientific Reports, Vol. 11, Núm. 1

  7. Plasma concentrations of lysophosphatidic acid and autotaxin in abstinent patients with alcohol use disorder and comorbid liver disease

    Biomedicines, Vol. 9, Núm. 9

  8. Trastorno por uso de cocaína y depresión: Cuando el diagnóstico clínico no es suficiente

    Adicciones: Revista de socidrogalcohol, Vol. 33, Núm. 3, pp. 193-200

2020

  1. Abstinent patients with alcohol use disorders show an altered plasma cytokine profile: Identification of both interleukin 6 and interleukin 17A as potential biomarkers of consumption and comorbid liver and pancreatic diseases

    Journal of Psychopharmacology, Vol. 34, Núm. 11, pp. 1250-1260